A Randomized, Double-Blind, Two-Arm Placebo-Controlled, Parallel-Group, Multicenter Study of Rimonabant 20 mg Once Daily in the Treatment of Atherogenic Dyslipidemia in Abdominally Obese Patients.
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2012
At a glance
- Drugs Rimonabant (Primary)
- Indications Atherosclerosis; Dyslipidaemias; Lipid metabolism disorders; Obesity
- Focus Pharmacodynamics; Registrational
- Acronyms ADAGIO-LIPIDS
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 14 Apr 2009 Actual initiation date changed from Jun 2005 to May 2005 as reported by ClinicalTrials.gov.
- 01 Mar 2009 Results published in Arteriosclerosis and Thrombosis.